Status:
UNKNOWN
the Effect Between Platelet Reactivation and Antiplatelet Drugs
Lead Sponsor:
Beijing Anzhen Hospital
Conditions:
Drug Effect Disorder
Platelet Procoagulant Activity Deficiency
Eligibility:
All Genders
Brief Summary
Different antiplatelet drugs played various role in coronary artery disease. The mechanisms were unclear. Platelet reactivation maybe was one of major causes. Compared with clopidogrel, Ticagrelor is ...
Detailed Description
All admission patients were divided into two groups, the first group were prescribed loading dose (180 mg) ticagrelor, the second group were prescribed with 90 mg ticagrelor. We measured both platelet...
Eligibility Criteria
Inclusion
- coronary artery disease, percutaneous coronary intervention
Exclusion
- high risk bleeding patient, allergic to the drugs
Key Trial Info
Start Date :
May 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT02198053
Start Date
May 1 2014
End Date
December 1 2015
Last Update
July 22 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Anzhen Hospital
Beijing, China, 100029